Growth Metrics

Whitehawk Therapeutics (WHWK) Shares Outstanding (Weighted Average) (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Shares Outstanding (Weighted Average) for 8 consecutive years, with $39.6 million as the latest value for Q1 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) rose 46.92% to $39.6 million in Q1 2025 year-over-year; TTM through Mar 2025 was $39.6 million, a 46.92% increase, with the full-year FY2024 number at $27.0 million, changed 0.42% from a year prior.
  • Shares Outstanding (Weighted Average) was $39.6 million for Q1 2025 at Whitehawk Therapeutics, up from $27.0 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $39.6 million in Q1 2025 to a low of $2.5 million in Q1 2021.
  • A 5-year average of $21.2 million and a median of $26.9 million in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): tumbled 93.74% in 2021, then soared 723.76% in 2022.
  • Whitehawk Therapeutics' Shares Outstanding (Weighted Average) stood at $8.9 million in 2021, then skyrocketed by 152.27% to $22.5 million in 2022, then grew by 19.58% to $26.9 million in 2023, then rose by 0.42% to $27.0 million in 2024, then skyrocketed by 46.66% to $39.6 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Shares Outstanding (Weighted Average) are $39.6 million (Q1 2025), $27.0 million (Q4 2024), and $27.0 million (Q3 2024).